News – Page 32 – Alligator Bioscience

2018-05-08

New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 presented by Alligator Bioscience and Aptevo Therapeutics

ALG.APV-527 is Designed to Strategically Target and Engage the Immune System for the Potential Treatment of Multiple Solid Tumor Indications ...

2018-05-03

– Unique binding profile and cross-linking properties – Oral presentation at Protein Engineering Summit in Boston, ...

2018-04-26

Lund, Sweden, 26 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-04-26

Regulatory

Positive preclinical data for ATOR-1015 "Data provide strong support for our claims that ATOR-1015 is a next generation bispecific CTLA- ...

2018-04-18

Lund, Sweden, 18 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-04-17

Lund, Sweden, 17 April 2018 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceutic ...

2018-04-05

Lund, Sweden, 5 April – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals fo ...

2018-03-22

Regulatory

Lund, Sweden, 22 March – Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals f ...

2018-03-22

The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedis ...